Respiporc FLUpan H1N1
Porcine influenza vaccine (inactivated)
Table of contents
Overview
Respiporc FLUpan H1N1 is a vaccine used to protect pigs from eight weeks of age against swine influenza caused by pandemic subtype H1N1. Swine influenza or swine flu is a disease of the lungs and airways in pigs. Signs can include fever, depression, coughing, sneezing, difficulty breathing and loss of appetite. The vaccine can also be used during pregnancy up to three weeks before expected farrowing and during lactation.
The vaccine contains inactivated (killed) influenza A virus/Jena/VI5258/2009(H1N1)pdm09, a strain of the virus that causes swine influenza.
Authorisation details
Product details | |
---|---|
Name |
Respiporc FLUpan H1N1
|
Agency product number |
EMEA/V/C/003993
|
Active substance |
Influenza A virus/human strain: A/Jena/VI5258/2009 (H1N1)pdm09, inactivated
|
International non-proprietary name (INN) or common name |
Porcine influenza vaccine (inactivated)
|
Species |
Pigs
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI09AA03
|
Publication details | |
---|---|
Marketing-authorisation holder |
CEVA Santé Animale
|
Revision |
6
|
Date of issue of marketing authorisation valid throughout the European Union |
17/05/2017
|
Contact address |
10 avenue de La Ballastière |
Product information
04/11/2021 Respiporc FLUpan H1N1 - EMEA/V/C/003993 - II/0013
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Immunologicals, inactivated viral vaccines for pigs, porcine influenza virus
Therapeutic indication
Active immunisation of pigs from the age of 8 weeks onwards against pandemic H1N1 porcine influenza virus to reduce viral lung load and viral excretion.
The vaccine can be used during pregnancy up to three weeks before expected farrowing and during lactation lactation.